A Phase-2 Study to Evaluate the Ability of HT-6184 to Attenuate Diagnostic Biomarkers of Post-procedure Acute Inflammation and Manage Pain Following Third Molar Extraction
Latest Information Update: 11 Sep 2024
At a glance
- Drugs HT-6184 (Primary)
- Indications Inflammation; Pain
- Focus Adverse reactions; Therapeutic Use
- Sponsors Halia Therapeutics
Most Recent Events
- 10 Sep 2024 According to a Halia media release, the company will present results from this trial at the upcoming 6th Inflammasome Therapeutics Summit taking place September 10-12, 2024, in Boston, MA
- 18 Jul 2024 Status changed from recruiting to completed.
- 17 Apr 2024 According to a Halia media release, the study will be presented at Asia BIO 2024